Benefit from Early Treatment of Secondary Progressive MS Appears Persistent Up to 7 Years

STR1VE-EU: Gene Replacement Therapy in Symptomatic Spinal Muscular Atrophy Is Associated with Substantial Benefit

Gene Therapy for Spinal Muscular Atrophy Effective as First- or Second-line Therapy

Head-to-Head Trial Shows Large Clinical Advantage for CGRP Monoclonal Antibody in Migraine Prophylaxis

Efficacy of Spinal Muscular Atrophy Therapies Depends on Early Initiation

Spinal Muscular Atrophy Remains Controlled in a Phase 3 Study with New Gene Therapy: SPR1NT Trial

Cognitive Function as an Endpoint in Secondary Progressive Multiple Sclerosis

Targeted Agent Found Better than Immunomodulator as First-Line Strategy for Relapsing Multiple Sclerosis

Extended Protection from Disability and Cognitive Dysfunction
Seen in Active SPMS

Relapsing-Remitting Multiple Sclerosis and High-efficacy Therapies

Relapsing-Remitting Multiple Sclerosis: Oral First-line Immunomodulators

Delays in Progression of Secondary-Progressive Multiple Sclerosis Persist at 5 years